Tony Berberabe, MPH

Articles

Higher PFS Rate Reported for Encorafenib/Binimetinib Combo Followed by Immunotherapy in Metastatic Melanoma

September 19th 2020

Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.

More Frequent Dosing of Lanreotide Autogel Delays the Use of More Toxic Treatments in Pancreatic, Midgut NETs

September 19th 2020

Improvements in disease-free survival and progression-free survival were observed in patients with progressive pancreatic or midgut neuroendocrine tumors whose frequency of dosing for lanreotide Autogel was increased from 120 mg every 28 days to every 14 days.

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC

May 31st 2020

The use of cabazitaxel over abiraterone acetate or enzalutamide may continue as a standard of care in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma

May 30th 2020

The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.

Updated CARTITUDE-1 Results Continue to Demonstrate Safety, Durable Responses for JNJ-4528 in R/R Multiple Myeloma

May 29th 2020

The chimeric antigen receptor T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial.

Using a Multinational Pediatric Cancer Registry Helps to Improve PFS in High-Risk Patients

May 29th 2020

The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.

Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL

April 29th 2020

A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.

Capmatinib Shows Clinical Meaningful Activity and Intracranial Responses in MET Exon 14+ NSCLC

April 28th 2020

Results from the GEOMETRY mono-1 study demonstrated antitumor efficacy of and deep and durable responses with capmatinib in 97 patients with advanced non–small cell lung cancer who harbor MET exon 14 mutations.

ASCO Guidelines on VTE Add New Oral Agents

November 19th 2019

Updated venous thromboembolism (VTE) guidelines issued by the American Society of Clinical Oncology now include the use of direct oral anticoagulants for patients with cancer as a preventive measure against VTE recurrence.

Taking CLL Therapies From Bedside to Community

November 3rd 2019

Michael J. Keating, MBBS, has devoted much of his career to finding means of controlling chronic lymphocytic leukemia.

Advances in Small Bowel Cancer Generate New NCCN Guidelines

October 20th 2019

A new set of recommendations for the treatment of small bowel adenocarcinoma, a relatively rare type cancer of the gastrointestinal tract, have been created by the National Comprehensive Cancer Network. The guidelines are the first in the United States and second in the world to recommend treatments specific to the malignancy, which is often diagnosed at advanced stages.

Liver-Directed Therapies Enhance Treatment Landscape for Metastatic NETs

October 9th 2019

Patients with neuroendocrine tumors that have metastasized to the liver derive clinical benefit from locoregional therapies, but treatment guidelines for employing these strategies must be more fully developed.

Kumar Discusses Path Forward for Venetoclax in Myeloma

September 16th 2019

Shaji Kumar, MD, discusses the addition of the BCL-2 inhibitor venetoclax to the combination of bortezomib and dexamethasone significantly improved progression-free survival, overall response rate, very good partial response, and minimal residual disease negativity rates in the phase III BELLINI trial in relapsed/refractory patients with multiple myeloma.

Isatuximab Triplet Showcases Encouraging PFS in High-Risk Multiple Myeloma

September 15th 2019

Adding the CD38-directed monoclonal antibody isatuximab in combination with pomalidomide and dexamethasone improved progression-free survival in both standard-risk patients with relapsed/refractory multiple myeloma and those with high-risk cytogenetics.

Daratumumab-VTd Regimen Shows Benefit in Newly Diagnosed High-Risk Multiple Myeloma

September 14th 2019

Pieter Sonneveld, MD, PhD, discusses the significance of the subgroup analysis of the phase III CASSIOPEIA trial evaluating the regimen of daratumumab, bortezomib, thalidomide, and dexamethasone in patients with high-risk multiple myeloma.

New Strategies Are Evolving for Breast Cancer Brain Metastases

August 27th 2019

A greater focus on studying mechanisms for therapies that penetrate the blood–tumor barrier and the expansion of clinical trial eligibility criteria are opening the door for advancements that may help patients with metastatic breast cancer that has spread to the brain, according to Carey K. Anders, MD.

Clinical Factors Help Define Use of Radionuclide Therapy in Neuroendocrine Tumors

July 5th 2019

Radiopharmaceuticals have been integrated into the treatment paradigm for patients with neuroendocrine tumors, yet there are nuances in the clinical scenarios in which they are most effective.

New Biomarkers for Responses Are Explored in Late-Stage Ovarian Cancer

July 4th 2019

The identification of appropriate biomarkers for evaluating responses to therapy would be beneficial across all stages of ovarian cancer, from early to advanced.

Oncology Practices Can Preserve Independence With a Strong Marketing Effort

June 29th 2019

From 2016 to 2018, there was an 8% increase in the number of community oncology practices consolidated into hospital systems, and this trend has many independent practices struggling to avoid the same fate. Two winning strategies are emerging to help practices remain independent.

Early Findings Show Activity for Cytokine Agonist in BCG-Unresponsive Bladder Cancer

June 27th 2019

Use of a cytokine agonist in combination with BCG was highly successful in stimulating an immune response in previously BCG-unresponsive patients with carcinoma in situ high-grade nonmuscle invasive bladder cancer, according to early trial results presented by Sam S. Chang, MD, MBA, at the 2019 American Urological Association Annual Meeting.